Abstract 141P
Background
Immunotherapy based on Immune Checkpoint Inhibitors (ICI) has changed the management of advanced Non-Small Cell Lung Cancer (NSCLC), achieving long-time responders for the first time. However, response rates remain below 40%. A deeper understanding of ICI response mechanisms and the identification of predictive biomarkers is still an urgent need. A close relation between DNA methylation and the immunogenic status of the tumor microenvironment (TME) has been recently proposed for several solid tumors. In this work we evaluated the epigenetic and transcriptomic status of NSCLC tumors before immunotherapy to disclose the possible role of DNA methylation in ICI response, and to identify immune-related signatures that predict ICI outcome.
Methods
We included 24 advanced NSCLC patients treated with anti-PD1 at first line. DNA and RNA were extracted from FFPE tumor biopsies. Genome-wide DNA methylation was quantified with the MethylationEPIC array and RNA-seq was performed with a NovaSeq6000 system. Data was annotated to the GRCh38 genome and bioinformatics was performed with R/Bioconductor.
Results
Differential methylation and expression patterns were found between patients with radiological response (n=10) and non-responder patients (n=14). We identified a DNA methylation signature that predicts a 6-months response to anti-PD1 therapy. Also, we reported a methylation profile associated with longer progression-free survival (PFS). Functional consequences of differential DNA methylation were confirmed by RNA-seq, identifying dysregulated immune pathways significantly enriched for both methylation and transcriptomic signatures. Pathways associated to ICI response related to T-cell and toll-like receptors signaling pathways, MHC-II complex, and interleukins. We also found aberrant methylation of the PI3K-Akt signaling pathway, which plays an essential role in the TME, regulating immune checkpoints and the sensitivity to ICI.
Conclusions
Overall, our results confirm that DNA methylation plays a role in the response to ICI in advanced NSCLC. These immune-related methylation profiles can predict response to anti-PD1 therapy and correlate with longer PFS, representing a source of predictive biomarkers for ICI outcome.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
This research project is funded by the national Institute of Health Carlos III (ISCIII, PI21/00348). M.M-F. is supported by the Miguel Servet program (CP20/00188) from the ISCIII and the European Social Fund (“Investing in your future”).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
72P - Role of pyruvate carboxykinase 2 upregulation in group 3 medulloblastoma: Implications for metabolic reprogramming and therapeutic strategies
Presenter: MEDHA GAYATHRI PAI
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - Effect of combination therapy with atezolizumab plus metformin on peripheral immune cells from NSCLC patients
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis
Presenter: Lysanne Desharnais
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Possible significance of the proline at position 325 in the recognition of the MX35 epitope of the NaPi2b transporter by monoclonal antibodies
Presenter: Leisan Bulatova
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression
Presenter: Simon Milette
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Daily rhythmic expression of pro-tumoral programs in NSCLC shape cancer immunity and therapy response
Presenter: Alba de Juan
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Single-cell spatial landscape of NSCLC reveals subtype specific immune features
Presenter: Mark Sorin
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation
Presenter: XIAOHE ZHOU
Session: Cocktail & Poster Display session
Resources:
Abstract